Hepion Pharmaceuticals, Inc.

OTCPK:HEPA Stock Report

Market Cap: US$1.2m

Hepion Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

John Brancaccio

Chief executive officer

US$565.1k

Total compensation

CEO salary percentage55.55%
CEO tenureless than a year
CEO ownership0.00006%
Management average tenureno data
Board average tenure2.5yrs

Recent management updates

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

CEO Compensation Analysis

How has John Brancaccio's remuneration changed compared to Hepion Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$565kUS$314k

-US$13m

Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$39m

Dec 31 2023US$81kn/a

-US$49m

Sep 30 2023n/an/a

-US$48m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$86kn/a

-US$45m

Sep 30 2022n/an/a

-US$45m

Jun 30 2022n/an/a

-US$46m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$394kn/a

-US$33m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$22m

Dec 31 2020US$304kn/a

-US$20m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$13m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$59kn/a

-US$12m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$20m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$59kn/a

-US$18m

Compensation vs Market: John's total compensation ($USD565.11K) is about average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Brancaccio (76 yo)

less than a year

Tenure

US$565,110

Compensation

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

Board Members

NamePositionTenureCompensationOwnership
John Brancaccio
Interim CEO12yrsUS$565.11k0.000060%
$ 0.7
Timothy M. Block
Independent Director11.5yrsUS$274.62k0.000060%
$ 0.7
Vlad Ratziu
Member of Scientific Advisory Board2.2yrsno datano data
Rohit Loomba
Member of Scientific Advisory Board2.2yrsno datano data
Stephen A. Harrison
Scientific Advisory Board Chair5.8yrsno datano data
Nikolai Naoumov
Member of Scientific Advisory Board2.2yrsno datano data
Philippe Gallay
Member of Scientific Advisory Board8.8yrsno datano data
Michael Purcell
Independent Director1.2yrsUS$174.06k0%
$ 0
Yury Popov
Member of Scientific Advisory Board2.2yrsno datano data
Kaouthar Lbiati
Independent Director2.9yrsUS$273.97k0%
$ 0

2.5yrs

Average Tenure

68yo

Average Age

Experienced Board: HEPA's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 02:22
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hepion Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Kumaraguru RajaBrookline Capital Markets
Kristen KluskaCantor Fitzgerald & Co.